Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 2
R&D Momentum
51/100
Pipeline Velocity
11/100
Trial Completion Rate
89/100
Pipeline Concentration
50/100
Pipeline Freshness
42/100
Strategic Signals
Activity
Last 14 days
Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation
Development of Neuroimaging Methods to Assess the Neurobiology of Addiction
Reliability Of The Human Brain Connectome
Brain Inflammation and Function in Alcoholism
Addictions Neuroclinical Assessment
Characterization of Brain Amyloid-beta (A-beta) Retention During Wakefulness And Following Emergence From Sleep In Healthy Subjects
The Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors
Nicotinic Receptor Genetic Variation and Alcohol Reward
Behavioral and Functional Task Development, Implementation, and Testing
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)